DermaRite Industries LLC recalled 11,321 bags of DermaKleen antiseptic lotion soap on July 17, 2025. The product, contaminated with Burkholderia cepacia, poses a serious health risk. Consumers should stop using the product immediately and contact health providers for guidance.
Microbial Contamination of Non-Sterile Drug Product: The products were found to be contaminated with the bacteria Burkholderia cepecia.
Consumers and healthcare providers should stop using this product immediately. Contact DermaRite Industries, LLC or your healthcare provider for guidance. Notification method: Letter
Get instant alerts for Health & Personal Care recalls
Be the first to know. Free instant alerts to your inbox.
The recalled DermaKleen antiseptic lotion soap is available in 800 ml (27 fl. oz.) and 1000 ml (34 fl. oz.) bag-n-boxes. The affected NDC numbers are 61924-092-27 and 61924-092-34. The products were distributed nationwide.
The product contains Burkholderia cepacia, a bacteria that can cause serious infections, particularly in individuals with weakened immune systems. The contamination classifies the recall as Class I, indicating a high level of risk.
There have been no reported injuries related to this contamination. However, Burkholderia cepacia can lead to significant health complications.
Consumers should stop using the product immediately. Contact DermaRite Industries, LLC or your healthcare provider for further guidance. Notifications have been sent via letter.
For more information, contact DermaRite Industries at 1-800-XXX-XXXX or visit their website at www.dermarite.com.
Get instant alerts for recalls that affect you. Free forever.
Taro Pharmaceuticals announced a market withdrawal of Diclofenac Sodium, Topical Gel, 3% on January 27, 2026. The withdrawal stems from out of specification viscosity results. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,057 bags of Acyclovir Sodium Injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers should cease use immediately and contact the manufacturer for guidance.
Fresenius Kabi Compounding recalled its vancomycin HCl injection on February 5, 2026, due to a lack of assurance of sterility. This Class II recall affects all lots distributed nationwide. Healthcare providers and consumers must stop using the product immediately.
Fresenius Kabi Compounding recalled 1,578 bags of vancomycin HCl injection on February 5, 2026. The company cited a lack of assurance of sterility as the reason for the recall. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,410 bags of ketamine HCl injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers and consumers must stop using this product immediately.
Fresenius Kabi Compounding recalled 10,548 bags of thiamine HCl injection on February 5, 2026. The recall follows a lack of assurance of sterility, posing a high health risk. Affected products include several lots expiring between February and May 2026.
Pro Numb Tattoo Numbing Spray was recalled due to cGMP deviations. The recall affects products distributed nationwide in the USA. Consumers should stop using the spray immediately and contact Pro Numb Tattoo Numbing Spray LLC for guidance.
Pro Numb Tattoo Numbing Spray was recalled on February 2, 2026 due to cGMP deviations. The product, containing 4% lidocaine, is distributed by Pro Numb Tattoo Numbing Spray LLC. Consumers should stop using it immediately and contact the company for further guidance.